Login / Signup

Current Clinical Trial Landscape of OX40 Agonists.

Rashi YadavWilliam L Redmond
Published in: Current oncology reports (2022)
Numerous preclinical studies have demonstrated that OX40 agonists alone or in combination with ICB (e.g., anti-PD-1, anti-PD-L1, and anti-CTLA-4) augment anti-tumor immunity. In this review, we discuss the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.
Keyphrases
  • clinical trial
  • low density lipoprotein
  • randomized controlled trial
  • study protocol
  • cell therapy